Financial reports
10-K
2023 FY
Annual report
21 Feb 24
10-K/A
2022 FY
Annual report (amended)
20 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
3 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
Current reports
8-K
Departure of Directors or Certain Officers
15 Mar 24
8-K
Bone Biologics Announces Pricing of $2.0 Million Public Offering
6 Mar 24
8-K
Bone Biologics Reports Progress with NB1 Clinical Program
1 Mar 24
8-K
Other Events
12 Jan 24
8-K
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
11 Jan 24
8-K
Other Events
10 Jan 24
8-K
Departure of Directors or Certain Officers
2 Jan 24
8-K
Bone Biologics Announces 1-for-8 Reverse Stock Split
18 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
13 Dec 23
8-K
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
20 Nov 23
Registration and prospectus
424B4
Prospectus supplement with pricing info
4 Mar 24
S-1/A
IPO registration (amended)
26 Feb 24
S-1/A
IPO registration (amended)
23 Feb 24
S-1
IPO registration
30 Jan 24
S-3/A
Shelf registration (amended)
17 Jan 24
S-3
Shelf registration
5 Jan 24
D
$729.00 k in equity / options / securities to be acquired, sold $729.00 k, 4 investors
29 Nov 23
424B5
Prospectus supplement for primary offering
20 Nov 23
S-8
Registration of securities for employees
15 Sep 23
424B4
Prospectus supplement with pricing info
15 Jun 23
Proxies
DEF 14A
Definitive proxy
20 Nov 23
PRE 14A
Preliminary proxy
9 Nov 23
DEFA14A
Additional proxy soliciting materials
3 Aug 23
DEF 14A
Definitive proxy
3 Aug 23
DEF 14C
Information statement
11 May 23
PRE 14C
Preliminary information
1 May 23
DEF 14A
Definitive proxy
6 Jul 22
DEF 14C
Information statement
25 Jun 21
PRE 14C
Preliminary information
7 Jun 21
DEF 14A
Definitive proxy
10 Aug 18
Other
EFFECT
Notice of effectiveness
5 Mar 24
EFFECT
Notice of effectiveness
25 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
UPLOAD
Letter from SEC
11 Jan 24
EFFECT
Notice of effectiveness
15 Jun 23
CORRESP
Correspondence with SEC
13 Jun 23
CORRESP
Correspondence with SEC
13 Jun 23
UPLOAD
Letter from SEC
8 May 23
EFFECT
Notice of effectiveness
7 Oct 22
CORRESP
Correspondence with SEC
4 Oct 22
Ownership
SC 13G
INTRACOASTAL CAPITAL, LLC
14 Mar 24
SC 13G/A
Ionic Ventures, LLC
14 Feb 24
SC 13G/A
Walleye Capital LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
4
Deina H Walsh
19 Jan 24
4
Jeff Frelick
19 Jan 24
4
Robert E. Gagnon
10 Jan 24
3
Robert E. Gagnon
10 Jan 24
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G/A
Ionic Ventures, LLC
20 Dec 23